QFT | Jotup

Troilus Announces $15 Million Bought Deal Offering

Retrieved on:

Monday, October 30, 2023

Sale, Toronto Stock Exchange, OTCQX, Person, News, Oil Taxation Act 1975, Haywood, National instrument, TLG, Offering, QFT, Section 50C of the Isle of Man Income Tax Act 1970, TSX, Underwriting, Income Tax Act, Security (finance), Unit

MONTREAL, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (“Troilus” or the “Company”, TSX: TLG, OTCQX: CHXMF) is pleased to announce that it has entered into an agreement with Haywood Securities Inc. (“Haywood”), on behalf of themselves and a syndicate of underwriters to be formed (collectively, together with Haywood, the “Underwriters”) pursuant to which the Underwriters have agreed to purchase, on a bought deal public offering basis, (i) 28,580,000 units of the Company (the “Units”) at a price of C$0.35 per Unit (the “Unit Issue Price”), (ii) 7,150,000 traditional flow-through shares of the Company (the “FT Shares”) at a price of C$0.42 per FT Share (the “FT Issue Price”); and (iii) 4,550,000 Québec flow-through shares of the Company (the “QFT Shares” and together with the Units and FT Shares, the “Offered Securities”) at a price of C$0.44 per QFT Share (the “QFT Issue Price”), representing total gross proceeds to the Company of C$15,008,000 (the “Offering”).

Key Points:

All Qualifying Expenditures will be renounced in favour of the subscribers of the FT Shares and QFT Shares effective December 31, 2023.
The net proceeds from the sale of the Units will be used by the Company to fund exploration and development at the Company’s Troilus gold project, and for working capital and general corporate purposes.
The Offered Securities will be offered by way of short form prospectus in each of the provinces of Canada, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions.
The Offering is scheduled to close on or about November 20, 2023, subject to customary closing conditions, including receipt of all necessary approvals including the approval of the Toronto Stock Exchange (“TSX”).

THX Ltd. Announces New THX Interconnect Cables to Elevate Home Theater Entertainment

Retrieved on:

Wednesday, August 30, 2023

SAN FRANCISCO, Aug. 30, 2023 /PRNewswire/ -- THX Ltd., a world-class high-fidelity audio and video tuning, certification, and technology company, today announced it is launching THX® Interconnect, designed in partnership with Pixelgen. THX Interconnect are a family of Ultra High Speed HDMI® 2.1 cables capable of delivering 100% uncompressed 48Gbps signaling to optimize the fidelity and reliability of nearly any sized or configured home theater system. THX is also relaunching its popular home theater installer THX® Certified Training series. Both will be highlighted in early September in Denver, Colorado at the CEDIA Expo.

Key Points:

New THX® Interconnect cables provide reliable high-bandwidth signal delivery and full HDMI 2.1 functionality.
"The THX mission is to empower high-fidelity entertainment, regardless of where and how consumers want to enjoy movies, music and games," said Jason Fiber, chief executive officer, THX Ltd. "The THX Interconnect cables ensure all home theater components work in harmony at the highest resolutions, regardless of the length.
THX Interconnect cables are ideal for everyone who enjoys movies, music, gaming, sporting events, and streaming content at home over their TV, projector, or personal computer display.
Also, at CEDIA Expo, THX will reintroduce its ever popular THX Certification Training for home theater installers, distributors, and enthusiasts.

QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk

Retrieved on:

Wednesday, May 3, 2023

Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk.

Key Points:

Venlo, the Netherlands, and Germantown, Maryland, May 03, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it welcomed the U.S. Preventive Services Task Force (USPSTF) reaffirming a previously issued recommendation for latent tuberculosis infection (LTBI) screening by primary care physicians in populations at increased risk.
The USPSTF recommendations referred to QuantiFERON-TB Gold Plus (QFT-Plus) from QIAGEN as reliable in screening.
It also suggested that interferon gamma release assays (IGRAs) like QFT-Plus may have advantages in certain patient populations over the tuberculin skin test (TST) in a wider group of people at risk for latent TB infection.
This ongoing recommendation from the USPSTF supports the continued use of QuantiFERON-TB Gold Plus as part of the global fight against TB.

Canada Silver Cobalt Closes First Tranche of Private Placement

Retrieved on:

Friday, April 14, 2023

Unit, TSX Venture Exchange, FSE, CCW, QFT, Anomaly, Regulation, Security (finance), Exchange

Coquitlam, British Columbia--(Newsfile Corp. - April 14, 2023) - Canada Silver Cobalt Works Inc. (TSXV: CCW) (OTCQB: CCWOF) (FSE: 4T9B) (the "Company" or "Canada Silver Cobalt") announces that the Company has closed the first tranche of a non-brokered private placement by way of issuing 6,950,000 non-flow-through units ("Units") at a price of $0.05 per Unit raising gross proceeds of $347,500.

Key Points:

Coquitlam, British Columbia--(Newsfile Corp. - April 14, 2023) - Canada Silver Cobalt Works Inc. (TSXV: CCW) (OTCQB: CCWOF) (FSE: 4T9B) (the "Company" or "Canada Silver Cobalt") announces that the Company has closed the first tranche of a non-brokered private placement by way of issuing 6,950,000 non-flow-through units ("Units") at a price of $0.05 per Unit raising gross proceeds of $347,500.
Additional finder's fees will be paid on behalf of the private placement.
The private placement is subject to final TSX Venture Exchange ("Exchange") approval.
The proceeds of the QFT private placement will be used for drill testing the recently staked Bouguer gravity anomalies and existing Ni-Cu showings in Quebec.

QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework

Retrieved on:

Tuesday, February 14, 2023

Biotechnology, Medical Devices, Health, Genetics, Pharmaceutical, Gold, QIAGEN, Diagnosis, Tuberculosis, NYSE, IVDR, Patient, IVDD, Certification, Senior, Notified body, QFT, WHO, QGEN, IVD, EC, FDA, Bacteria, TB, JAK2, Medical device, EU, European

QFT-Plus is QIAGEN’s trusted test, endorsed by the WHO, that aids in indirect detection of the bacteria that causes tuberculosis (TB).

Key Points:

QFT-Plus is QIAGEN’s trusted test, endorsed by the WHO, that aids in indirect detection of the bacteria that causes tuberculosis (TB).
The IVDR certification of QFT-Plus follows the QIAGEN ipsogen JAK2 RGQ PCR Kit as well as the NeuMoDx Systems and reagents, which gained IVDR CE-marking in late 2022.
“Our teams have been able to demonstrate that QuantiFERON-TB Gold Plus is compliant to the IVDR requirements through stringent regulatory review.
For more information about the transition from IVDD to IVDR and the corresponding time frame, please visit the IVDR support site .

IAPMO R&T Lab Acquires QFT Laboratory, Hires Jaime Young as Lab Director

Retrieved on:

Monday, December 12, 2022

Water, Lab, Drinking water, QFT, Quality, Research, NSF, IAPMO, Acquisition, Bottled water, Drug, Heating, ventilation, and air conditioning

QFT Lab Director Jaime Young will join IAPMO to assist in the provision of similar services.

Key Points:

QFT Lab Director Jaime Young will join IAPMO to assist in the provision of similar services.
"IAPMO R&T Lab's newest laboratory in New Jersey, under the supervision of Lab Director Jaime Young, will complement our water filtration lab in Ontario, California, in serving our clients' water filtration testing needs to various IAPMO and NSF/ANSI standards."
"I'm excited to join IAPMO R&T Lab and combine a world-class Water Systems Certification Program with what we have built at QFT," Young said.
IAPMO Testing and Services, LLC, d/b/a IAPMO R&T Lab, is part of The IAPMO Group's family of companies.

QIAGEN Issues 2021 Sustainability Report

Retrieved on:

Thursday, August 18, 2022

In 2021, QIAGEN lowered its greenhouse gas intensity, i.e., its Scope 1 and 2 emissions divided by net sales, by 16% compared to the previous year.

Key Points:

In 2021, QIAGEN lowered its greenhouse gas intensity, i.e., its Scope 1 and 2 emissions divided by net sales, by 16% compared to the previous year.
For example, QIAGEN introduced plant-based material alternatives either based on straw or paper to replace the expanded polystyrene coolers in cold-chain shipments in 2021.
QIAGEN launched QIAreach QuantiFERON-TB (QIAreach QFT), a test featuring ultrasensitive digital detection built into a fully portable device, in October 2021.
For its sustainability efforts QIAGEN was recognized by the rating agencies ISS-ESG, MSCI as well as Sustainalytics which all specialize in sustainability.

QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB

Retrieved on:

Thursday, March 24, 2022

Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, NYSE, Research, SEC, CEO, TB, Tuberculosis, Automation, Solution, Disease, Gold, Molecular diagnostics, Knowledge, IRD, Lymphocyte, QIAGEN, Lyme disease, Pregnancy, Achievement, Death, QuantiFERON, Global, Workflow, U.S. Securities and Exchange Commission, Genetically modified bacteria, Deep Ellum, Dallas, Budget, IGRA, Life, World Health Organization, WHO, DNA, World Tuberculosis Day, QFT, Growth, World, Severe acute respiratory syndrome coronavirus 2, GDF, Review, Interferon, QGEN, Protein, Patient, Infection, LTBI, Partnership, Stop TB Partnership, BCG, Globe, Antigen, RNA, Food, Transmission, US Foods, UNITAID, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Blood, Vaccine, Pharmaceutical industry, Pharma, Insight, Academy

10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.

Key Points:

10 million people developed active TB disease in 2020, and they could have been identified and treated before they developed clinical symptoms and transmissible infection.
Today is World TB Day, a chance to remind the world that most of the 1.5 million annual deaths are avoidable.
The milestone of 100 million tests is an important signal on World TB Day.
In 2020, the World Health Organization (WHO) estimates that there were 10 million new cases of active TB worldwide and 1.5 million deaths from TB.

QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

Retrieved on:

Monday, February 7, 2022

Research, Medical Supplies, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Policy, Chinese Academy of Medical Sciences COVID-19 vaccine, Knowledge, LTBI, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Senior, RNA, QFT, Automation, Growth, GDF, QIAGEN, Protein, Research, Solution, HIV, Infection, Molecular diagnostics, Interferon gamma release assay, Technology, Budget, U.S. Securities and Exchange Commission, Global, Diagnosis, Institute, Blood, UNITAID, SEC, Method, DNA, Life, Stop TB Partnership, Institute of Biophysics, Chinese Academy of Sciences, Central business district, QuantiFERON, NMPA, IGRA, Non-functional testing, Disease, Diabetes, Immunodeficiency, National Medical Products Administration, WHO, Medicine, Tuberculosis, TST, Pharmaceutical industry, Vaccine, Insight, TB, Academy, Pharma

Since 2013, more than 1.5 million people in China have been tested for active TB infection using the proprietary QuantiFERON technology.

Key Points:

Since 2013, more than 1.5 million people in China have been tested for active TB infection using the proprietary QuantiFERON technology.
The WHO has renewed its recommendation that blood-based Interferon-Gamma Release Assays (IGRA) are an alternative for the diagnosis of TB infection, in addition to the Tuberculin Skin Test (TST).
QIAreach QFT was launched in late 2021 and was recently approved by the Global Funds Expert Review Panel Diagnostics (ERPD).
"The world needs new technologies and methods to contest TB and QIAGENs IGRA technology is playing a crucial role here.

QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

Retrieved on:

Thursday, January 6, 2022

A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma that is released from T-cells that have come into contact with TB bacteria.

Key Points:

A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma that is released from T-cells that have come into contact with TB bacteria.
We are determined to further expand the range of applications for our immune response technology in the coming years.
QIAGEN is experiencing strong customer interest in the QuantiFERON SARS-CoV-2 assay, which was launched in December 2021 and has now received a European CE mark.
For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).